Logo image of FLXN

Flexion Therapeutics (FLXN) Stock Fundamental Analysis

NASDAQ:FLXN - Nasdaq -

9.12  -0.02 (-0.22%)

After market: 9.121 +0 (+0.01%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to FLXN. FLXN was compared to 571 industry peers in the Biotechnology industry. FLXN has a bad profitability rating. Also its financial health evaluation is rather negative. FLXN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year FLXN has reported negative net income.
FLXN Yearly Net Income VS EBIT VS OCF VS FCFFLXN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 -50M -100M -150M

1.2 Ratios

Industry RankSector Rank
ROA -46.22%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FLXN Yearly ROA, ROE, ROICFLXN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 0 200 400 600

1.3 Margins

Industry RankSector Rank
OM -78.17%
PM (TTM) -100.33%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FLXN Yearly Profit, Operating, Gross MarginsFLXN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 0 -10K -20K -30K

More info and screens

3

2. Health

2.1 Basic Checks

FLXN has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, FLXN has about the same debt to assets ratio.
FLXN Yearly Shares OutstandingFLXN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 10M 20M 30M 40M
FLXN Yearly Total Debt VS Total AssetsFLXN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 100M 200M 300M 400M

2.2 Solvency

FLXN has an Altman-Z score of -4.56. This is a bad value and indicates that FLXN is not financially healthy and even has some risk of bankruptcy.
A Debt/Equity ratio of -3.04 indicates that FLXN is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity -3.04
Debt/FCF N/A
Altman-Z -4.56
ROIC/WACCN/A
WACCN/A
FLXN Yearly LT Debt VS Equity VS FCFFLXN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 4.38 indicates that FLXN has no problem at all paying its short term obligations.
FLXN has a Quick Ratio of 4.05. This indicates that FLXN is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 4.38
Quick Ratio 4.05
FLXN Yearly Current Assets VS Current LiabilitesFLXN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

FLXN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.59%, which is quite impressive.
Looking at the last year, FLXN shows a very strong growth in Revenue. The Revenue has grown by 21.13%.
FLXN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 519.40% yearly.
EPS 1Y (TTM)33.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.66%
Revenue 1Y (TTM)21.13%
Revenue growth 3Y519.4%
Revenue growth 5YN/A
Sales Q2Q%-9.86%

3.2 Future

The Earnings Per Share is expected to grow by 7.86% on average over the next years.
FLXN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 36.37% yearly.
EPS Next Y18.99%
EPS Next 2Y20.75%
EPS Next 3Y19.88%
EPS Next 5Y7.86%
Revenue Next Year26.13%
Revenue Next 2Y35.91%
Revenue Next 3Y35%
Revenue Next 5Y36.37%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
FLXN Yearly Revenue VS EstimatesFLXN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M
FLXN Yearly EPS VS EstimatesFLXN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

FLXN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year FLXN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FLXN Price Earnings VS Forward Price EarningsFLXN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -7.41
FLXN Per share dataFLXN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as FLXN's earnings are expected to grow with 19.88% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.75%
EPS Next 3Y19.88%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FLXN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Flexion Therapeutics

NASDAQ:FLXN (11/18/2021, 8:14:27 PM)

After market: 9.121 +0 (+0.01%)

9.12

-0.02 (-0.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-17 2021-11-17
Earnings (Next)03-09 2022-03-09/amc
Inst Owners4.44%
Inst Owner Change0%
Ins Owners19.2%
Ins Owner Change0%
Market Cap458.42M
Analysts78.67
Price Target12.62 (38.38%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.57
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA -7.41
EPS(TTM)-2.61
EYN/A
EPS(NY)-1.41
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS2
BVpS-1.64
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.22%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -78.17%
PM (TTM) -100.33%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity -3.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.38
Quick Ratio 4.05
Altman-Z -4.56
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.66%
EPS Next Y18.99%
EPS Next 2Y20.75%
EPS Next 3Y19.88%
EPS Next 5Y7.86%
Revenue 1Y (TTM)21.13%
Revenue growth 3Y519.4%
Revenue growth 5YN/A
Sales Q2Q%-9.86%
Revenue Next Year26.13%
Revenue Next 2Y35.91%
Revenue Next 3Y35%
Revenue Next 5Y36.37%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A